Klivira
Request demo

Aetna Rexulti Prior Authorization: A Guide for Revenue Cycle Teams

Successfully managing Aetna Rexulti prior authorization requests is critical for patient access and revenue integrity. Klivira provides the insights necessary to streamline these complex workflows.

Rexulti (brexpiprazole), an atypical antipsychotic indicated for schizophrenia and as an adjunctive treatment for major depressive disorder, frequently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. For revenue cycle directors and prior authorization coordinators, understanding Aetna's specific requirements is paramount to minimizing delays and denials.

Navigating Aetna's Prior Authorization for Rexulti

Rexulti, typically managed under the pharmacy benefit, requires prior authorization through Aetna's pharmacy benefit manager (PBM), CVS Caremark. This process involves specific clinical criteria to ensure medical necessity, often including documentation of previous treatment failures or specific diagnostic criteria outlined in Aetna's Clinical Policy Bulletins (CPBs).

Rexulti Prior Authorization Submission Channels for Aetna

Aetna, through CVS Caremark, supports various electronic prior authorization (ePA) channels for pharmacy benefit medications like Rexulti. Providers can leverage established ePA partners for retail pharmacy submissions or utilize direct portals for mail-order and case-managed scenarios.

Primary ePA Pathways for Rexulti with Aetna (CVS Caremark)

  • **ePA via CoverMyMeds:** Widely used for outpatient retail pharmacy prior authorizations.
  • **ePA via Surescripts:** Another robust platform supporting electronic pharmacy benefit prior authorization requests.
  • **CVS Caremark Provider Portal:** For direct submission of prior authorizations, particularly for mail-order prescriptions or complex case management.

Aetna's Clinical Policy and Utilization Management for Rexulti

Aetna's medical necessity criteria for Rexulti are detailed within its Clinical Policy Bulletins (CPBs), publicly accessible in the Aetna CPB library. These policies specify indications, duration of therapy, step therapy requirements, and any quantity limits. Reviewing the relevant, versioned CPB is essential for understanding the specific documentation needed for approval.

Common Denial Reasons for Rexulti Prior Authorizations with Aetna

Denials for Rexulti PA requests often stem from a few key areas. Providers should be prepared to address these proactively by ensuring comprehensive documentation that aligns with Aetna's published criteria. Denial reasons are typically communicated via X12 835/277 transactions or portal status updates, using standard CARC and RARC codes.

Frequent Denial Categories

  • **Medical Necessity / Insufficient Documentation:** Failure to provide adequate clinical evidence supporting the diagnosis or the necessity of Rexulti over alternative therapies.
  • **Step Therapy Requirements Not Met:** Lack of documented trials and failures of preferred formulary alternatives as mandated by Aetna's step therapy protocols.
  • **Off-Label Use:** Prescribing for an indication not approved by the FDA and not supported by recognized compendia or Aetna's CPBs.
  • **Quantity Limits Exceeded:** Requests exceeding the maximum dosage or quantity allowed by Aetna's formulary guidelines without clinical justification.

Navigating Aetna Rexulti PA Appeals

Should a Rexulti prior authorization be denied, Aetna offers a structured appeal process. This typically involves reconsideration, peer-to-peer review, and formal appeal levels, with expedited pathways available for urgent situations. Understanding the specific timely-filing windows and documentation requirements for each appeal stage is crucial for overturning initial denials.

Frequently asked questions

How do I submit a prior authorization for Rexulti to Aetna?

For Rexulti, which is a pharmacy benefit drug, prior authorizations are typically submitted electronically via ePA partners like CoverMyMeds or Surescripts. Alternatively, providers can use the CVS Caremark direct provider portal, especially for mail-order prescriptions. Ensure all clinical documentation is attached.

Where can I find Aetna's medical necessity criteria for Rexulti?

Aetna publishes its medical necessity criteria for all medications, including Rexulti, within its Clinical Policy Bulletins (CPBs). These CPBs are available in the public Aetna CPB library and outline specific indications, step therapy requirements, and other utilization management guidelines.

Does Aetna require step therapy for Rexulti?

Aetna's specific step therapy requirements for Rexulti are detailed within the relevant Clinical Policy Bulletin (CPB). It is common for atypical antipsychotics to have step therapy protocols, requiring trials of preferred agents before approval for Rexulti. Always consult the current CPB for the most accurate information.

What are common reasons for Rexulti PA denials by Aetna?

Common denial reasons include insufficient documentation of medical necessity, failure to meet step therapy requirements (e.g., not documenting trials of preferred alternatives), or prescribing for off-label uses not supported by Aetna's policies. Ensuring thorough documentation aligned with the CPB is key.

How does CMS-0057-F impact Rexulti prior authorizations for Aetna members?

CMS-0057-F applies to Aetna's Medicare Advantage and Medicaid managed care lines of business (e.g., Aetna Better Health). This rule mandates specific decision timeframes (72 hours for standard, 24 hours for expedited) and requires electronic PA API conformance by 2027, impacting how Rexulti PAs will be processed for these populations.

Related coverage

Other rexulti prior authorization by payer

Other rexulti prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo